Home / News / India News / Article / Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin

Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin

Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India's current COVID-19 vaccination drive. Russian vaccine Sputnik-V has also been approved for emergency use in India

  • WhatsAppBookmarkBookmark
Listen to this article :
Photo for representational purpose

Photo for representational purpose

Bharat Biotech has written to the India's drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday.

Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India's current COVID-19 vaccination drive. Russian vaccine Sputnik-V has also been approved for emergency use in India.

Read Next Story
COVID-19 deaths being under-reported, alleges Rahul Gandhi

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All